Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...
Tempest Therapeutics granted FTD from FDA for amezalpat
Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to amezalpat, ...
Nasdaq1mon
Tempest Therapeutics Receives FDA Orphan Drug Designation for Amezalpat in Hepatocellular Carcinoma Treatment
Tempest Therapeutics, Inc. announced that the FDA has granted Orphan Drug Designation to amezalpat (TPST-1120), a selective PPAR⍺ antagonist, for treating hepatocellular carcinoma (HCC), which ...
Hosted on MSN7mon
Tempest falls after new trial data for liver cancer therapy
Tempest Therapeutics (NASDAQ:TPST) shares dropped Thursday after the company updated data from an ongoing trial designed to test its PPAR⍺ antagonist, amezalpat (TPST-1120), as a first-line ...
Hosted on MSN1mon
FDA grants ODD to Tempest’s hepatocellular carcinoma treatment
The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective peroxisome proliferator-activated receptor alpha (PPAR-α) antagonist ...
Benzinga.com5mon
Tempest Therapeutics (NASDAQ:TPST) Stock Quotes, Forecast and News Summary
Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in ...
Yahoo Finance21d
Tempest Therapeutics, Inc. (TPST)
The stock options will vest over a four-ye Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal studyBRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE ...